290 related articles for article (PubMed ID: 25374905)
1. Cytoskeleton targeting value in prostate cancer treatment.
Martin SK; Kamelgarn M; Kyprianou N
Am J Clin Exp Urol; 2014; 2(1):15-26. PubMed ID: 25374905
[TBL] [Abstract][Full Text] [Related]
2. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
3. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
Begemann D; Anastos H; Kyprianou N
Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
[TBL] [Abstract][Full Text] [Related]
4. TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.
Paller C; Pu H; Begemann DE; Wade CA; Hensley PJ; Kyprianou N
Prostate; 2019 Jan; 79(1):31-43. PubMed ID: 30155899
[TBL] [Abstract][Full Text] [Related]
5. Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.
Livas L; Hasani S; Kyprianou N
Adv Exp Med Biol; 2020; 1296():183-198. PubMed ID: 34185293
[TBL] [Abstract][Full Text] [Related]
6. Profiling Prostate Cancer Therapeutic Resistance.
Wade CA; Kyprianou N
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
[TBL] [Abstract][Full Text] [Related]
7. Prostate tumor neuroendocrine differentiation via EMT: The road less traveled.
Dicken H; Hensley PJ; Kyprianou N
Asian J Urol; 2019 Jan; 6(1):82-90. PubMed ID: 30775251
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms navigating the TGF-β pathway in prostate cancer.
Cao Z; Kyprianou N
Asian J Urol; 2015 Jan; 2(1):11-18. PubMed ID: 29051866
[TBL] [Abstract][Full Text] [Related]
9. Anoikis in phenotypic reprogramming of the prostate tumor microenvironment.
Nepali PR; Kyprianou N
Front Endocrinol (Lausanne); 2023; 14():1160267. PubMed ID: 37091854
[TBL] [Abstract][Full Text] [Related]
10. Targeting anoikis resistance in prostate cancer metastasis.
Sakamoto S; Kyprianou N
Mol Aspects Med; 2010 Apr; 31(2):205-14. PubMed ID: 20153362
[TBL] [Abstract][Full Text] [Related]
11. Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization.
Cai G; Wu D; Wang Z; Xu Z; Wong KB; Ng CF; Chan FL; Yu S
Oncogene; 2017 Jan; 36(4):546-558. PubMed ID: 27321179
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelial-mesenchymal transition.
Hendrix LN; Hamilton DA; Kyprianou N
Expert Rev Endocrinol Metab; 2013 Jul; 8(4):403-416. PubMed ID: 30736155
[TBL] [Abstract][Full Text] [Related]
13. Anoikis and EMT: Lethal "Liaisons" during Cancer Progression.
Cao Z; Livas T; Kyprianou N
Crit Rev Oncog; 2016; 21(3-4):155-168. PubMed ID: 27915969
[TBL] [Abstract][Full Text] [Related]
14. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
Fujimoto N
J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond.
Nakazawa M; Kyprianou N
J Steroid Biochem Mol Biol; 2017 Feb; 166():84-90. PubMed ID: 27189666
[TBL] [Abstract][Full Text] [Related]
16. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
Altschuler J; Stockert JA; Kyprianou N
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
[TBL] [Abstract][Full Text] [Related]
17. Cofilin-1 signaling mediates epithelial-mesenchymal transition by promoting actin cytoskeleton reorganization and cell-cell adhesion regulation in colorectal cancer cells.
Sousa-Squiavinato ACM; Rocha MR; Barcellos-de-Souza P; de Souza WF; Morgado-Diaz JA
Biochim Biophys Acta Mol Cell Res; 2019 Mar; 1866(3):418-429. PubMed ID: 30296500
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar T; Yang JC; Gao AC; Evans CP
Transl Androl Urol; 2015 Jun; 4(3):365-80. PubMed ID: 26814148
[TBL] [Abstract][Full Text] [Related]
19. Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy.
Shiota M; Yokomizo A; Eto M
Front Oncol; 2015; 5():304. PubMed ID: 26793621
[TBL] [Abstract][Full Text] [Related]
20. Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis.
Matuszak EA; Kyprianou N
Expert Rev Endocrinol Metab; 2011 May; 6(3):469-482. PubMed ID: 23667383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
